Clodronate for treatment of bone metastases in hormone refractory prostate cancer

Hering, F.; Rodrigues, Pedro Luiz Coelho; Lipay, Marco Aurélio

doi:10.1590/s1677-55382003000300006

Cited by 13 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They might be used to treat pain related to bone metastases, 4,[8][9][10] to prevent bone osteoporosis after androgen-deprivation therapy, 5,10 to prevent skeletal events related to metastasis, 4 and even to delay or prevent metastasis formation as previously demonstrated in vitro. [11][12][13][14] The ongoing effects of bisphosphonates are being studied in clinical trials.…”

Section: Discussionmentioning

confidence: 99%

“…8 All patients in the control group migrated to the monthly clodronate group based on evidence of the benefits of previously studied protocols. 5,8,9 Patients were strictly followed with PSA, serum testosterone (every 6 months or less), bone scintigraphy and densitometry, thoracic plain x-ray (every 6 months), and computed tomography scan, when necessary.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Safety of I.V. Nonnitrogen Bisphosphonates on the Occurrence of Osteonecrosis of the Jaw: Long-Term Follow-Up on Prostate Cancer Patients

Rodrigues

Hering

Imperio

2015

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Safety of I.V. Nonnitrogen Bisphosphonates on the Occurrence of Osteonecrosis of the Jaw: Long-Term Follow-Up on Prostate Cancer Patients

Rodrigues

Hering

Imperio

2015

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

“…In a similar placebo-controlled trial in 209 patients with hormone-refractory prostate cancer, IV clodronate administered at 1,500 mg every 3 weeks did not significantly reduce pain intensity or analgesic consumption [29]. Several uncontrolled trials of clodronate have also reported reductions from baseline pain scores [36,38,53,56,61]. Although open-label clinical trials assessing pain response must be interpreted with caution, these studies involving primarily prostate cancer patients suggest that clodronate may provide a palliative benefit [36,38,53,56,61].…”

Section: Clodronatementioning

confidence: 97%

“…Several uncontrolled trials of clodronate have also reported reductions from baseline pain scores [36,38,53,56,61]. Although open-label clinical trials assessing pain response must be interpreted with caution, these studies involving primarily prostate cancer patients suggest that clodronate may provide a palliative benefit [36,38,53,56,61]. However, in comparison with pamidronate 90 mg over a 3-month period in patients with malignant bone disease, clodronate was not as effective in reducing bone pain [42].…”

Section: Clodronatementioning

confidence: 99%

Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

Costa

Badı́a²,

Chow

et al. 2008

Support Care Cancer

180

133

View full text Add to dashboard Cite

Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.

show abstract

“…Ernst et al 2003;Heidenreich et al 2005;Hering et al 2003;Rodrigues et al 2004;Saad and Eastham, 2010a;Saad et al 2004;Small et al 2003]. …”

Section: Castration-resistant Prostate Cancerunclassified

Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid

Aapro¹,

Saad²

2012

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Many patients with advanced genitourinary malignancies develop bone metastases, which can lead to potentially debilitating skeletal complications. Moreover, age-related bone loss and cancer treatments such as hormonal therapy for prostate cancer can weaken bone, placing patients at risk for osteoporotic fractures in addition to skeletal-related events (SREs) from bone metastases. Zoledronic acid, a bisphosphonate, is approved worldwide to reduce the risk of SREs in patients with bone metastases from solid tumors or bone lesions from multiple myeloma. Zoledronic acid, although underutilized in genitourinary malignancies, has long been the mainstay of treatment in patients with bone metastases, and can also help preserve bone during anticancer therapy. Recently, denosumab, a monoclonal antibody directed against the receptor activator of nuclear factor kappa-B ligand, was approved in the United States and the European Union for reducing the risk of SREs in patients with bone metastases from solid tumors. Denosumab (at a lower dose) is also approved in the European Union and the United States to treat androgen deprivation-induced bone loss in men with prostate cancer. In addition, preclinical rationale and emerging clinical data suggest that bone-modifying agents may be able to delay disease progression in genitourinary cancers, just as newly developed anticancer treatments have produced reductions in SREs, possibly by indirect effects on the disease course. This review article summarizes current data and ongoing studies to preserve bone health in patients with advanced genitourinary cancers. Keywords 441234T AU 421756287212441234M Aapro and F SaadTherapeutic Advances in Urology 2012Therapeutic Advances in Urology 4 (2) 86 http://tau.sagepub.com tumor-stimulating growth factors from the bone [Mundy, 2002]. The resulting vicious cycle of cancer growth and bone destruction can lead to skeletal-related events (SREs), including pathologic fractures, spinal cord compression, the need for palliative radiotherapy, surgery to bone, cementoplasty, and hypercalcemia of malignancy [Coleman, 2001]. Without bone-directed treatment, the majority of patients with advanced PC will experience an SRE during the course of their disease [Saad et al. 2004]. Moreover, in retrospective analyses of a 21-month, randomized, phase III, placebo-controlled trial in patients with bone metastases from solid tumors (excluding breast or prostate cancer) [Rosen et al. 2004], approximately 75% of patients in the RCC subset who did not receive bisphosphonate (BP) therapy developed an SRE [Saad and Lipton, 2005].Even before the development of bone metastases, bone health may be compromised in patients with GU cancers because of age-related osteoporosis and the detrimental effects of anticancer therapies on bone mineral density (BMD). This is most evident in the PC setting, wherein surgical or hormonal castration (androgen-deprivation therapy [ADT]) to lower testosterone levels is common in patients who have high-risk disease, or whose pros...

show abstract

Clodronate for treatment of bone metastases in hormone refractory prostate cancer

Cited by 13 publications

References 19 publications

Safety of I.V. Nonnitrogen Bisphosphonates on the Occurrence of Osteonecrosis of the Jaw: Long-Term Follow-Up on Prostate Cancer Patients

Safety of I.V. Nonnitrogen Bisphosphonates on the Occurrence of Osteonecrosis of the Jaw: Long-Term Follow-Up on Prostate Cancer Patients

Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid

Contact Info

Product

Resources

About